TrialJournal of acquired immune deficiency syndromes (1999)2018

Patient Self-Reported Adherence to Ritonavir-Boosted Darunavir Combined With Either Raltegravir or Tenofovir Disoproxil Fumarate/Emtricitabine in the NEAT001/ANRS143 Trial.

Adriana Ammassari et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.